drugset / Trial / NCT00972465
Study of Nimotuzumab to Treat Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-12
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 600 mg | — |
| Background | Irinotecan | Small molecule | 180 mg/m2 | — |